All In Biotech

Drug Trial Radar · NCT07282587

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

A Phase 2 Study of ONC206 in Advanced Pheochromocytoma and Paraganglioma

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Jan 2, 2026

Primary completion

Dec 15, 2028

Study completion Dec 15, 2028

Sponsor

Lead sponsor
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
Sponsor type
Industry
First posted
Dec 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-stage Phase 2 trial evaluating the efficacy and safety of ONC206 in participants with Pheochromocytoma and Paraganglioma (PCPG).

Conditions

  • Advanced Pheochromocytoma and Paraganglioma
  • PCPG

Interventions

  • ONC206Drug

    150 mg BID TIW

  • ONC206: Dose 1Drug

  • ONC206: Dose 2Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: Up to 36 months.

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • UCLA

    Los Angeles, California · Recruiting

  • Stanford

    Palo Alto, California · Recruiting

  • U of Colorado

    Aurora, Colorado · Recruiting

  • U of Michigan

    Ann Arbor, Michigan · Recruiting

  • Mayo-Rochester

    Rochester, Minnesota · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • Columbia University Irving Medical Center

    New York, New York · Recruiting

  • PENN

    Philadelphia, Pennsylvania · Recruiting

  • UTAH

    Salt Lake City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.